Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). The agreement includes an upfront payment of
“We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated
About
Aclaris Therapeutics Contact:
Senior Vice President, Investor Relations
484-639-7235
rdoody@aclaristx.com
Source: Aclaris Therapeutics, Inc.